Cargando…
A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus
OBJECTIVE: Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. MET...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673008/ https://www.ncbi.nlm.nih.gov/pubmed/28467293 http://dx.doi.org/10.1177/0961203317703495 |
_version_ | 1783276532909735936 |
---|---|
author | Chatham, W Chadha, A Fettiplace, J Kleoudis, C Bass, D Roth, D Gordon, D |
author_facet | Chatham, W Chadha, A Fettiplace, J Kleoudis, C Bass, D Roth, D Gordon, D |
author_sort | Chatham, W |
collection | PubMed |
description | OBJECTIVE: Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. METHODS: This was a Phase 4, open-label study (GSK BEL115470; NCT01597492) conducted in the United States. Patients were randomized (7:9) to receive a 23-valent pneumococcal vaccination four weeks prior to (pre-belimumab cohort) or 24 weeks after (belimumab-concurrent cohort) commencing four-weekly belimumab 10 mg/kg intravenous treatment plus standard systemic lupus erythematosus therapy. Analyses of vaccine titers were performed on the as-treated population (received ≥1 dose of belimumab). The primary endpoint was the proportion of patients with positive antibody responses (≥2-fold increase from pre-vaccination levels, or post-vaccination level ≥ 0.6 µg/mL if pre-vaccination levels were unquantifiable) to ≥1 of 23 pneumococcal vaccine serotypes, four weeks post vaccination. Other endpoints included the proportion of patients with positive antibody responses to ≥2 to ≥10, and ≥11–23 (post hoc analysis) of serotypes. Safety was assessed by monitoring adverse events. RESULTS: Seventy-nine patients received pneumococcal vaccination (pre-belimumab cohort, n = 34; belimumab-concurrent cohort, n = 45). The majority (87.3% [69/79]) completed the study; 10 (12.7%) withdrew (patient request, n = 3; adverse event, n = 3; lost to follow-up, n = 2; other, n = 2). At Week 4 post-vaccination, 97.0% (32/33) and 97.6% (40/41) of patients (pre-belimumab and concurrent belimumab cohorts, respectively) had a positive response to ≥1 of 23 pneumococcal serotypes. Over 85% of patients in both cohorts responded to ≥10 of serotypes, approximately 80% responded to ≥12 serotypes, and approximately two-thirds responded to ≥16 serotypes. Little difference was observed between cohorts across a broad response, up to 23 serotypes. Eight (23.5%) patients experienced an adverse event considered by the investigator to be treatment-related in the pre-belimumab cohort and four (8.9%) in the belimumab-concurrent cohort; seven patients experienced non-fatal serious adverse events (pre-belimumab cohort, 11.8% [n = 4]; concurrent-belimumab cohort, 6.7% [n = 3]), and no deaths were reported. CONCLUSION: The proportion of patients generating a response to ≥1 pneumococcal serotype did not differ between the pre-belimumab and belimumab-concurrent cohorts; the proportions were also comparable across a broader response (from ≥2 serotypes to 23 serotypes). |
format | Online Article Text |
id | pubmed-5673008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-56730082017-11-28 A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus Chatham, W Chadha, A Fettiplace, J Kleoudis, C Bass, D Roth, D Gordon, D Lupus Papers OBJECTIVE: Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. METHODS: This was a Phase 4, open-label study (GSK BEL115470; NCT01597492) conducted in the United States. Patients were randomized (7:9) to receive a 23-valent pneumococcal vaccination four weeks prior to (pre-belimumab cohort) or 24 weeks after (belimumab-concurrent cohort) commencing four-weekly belimumab 10 mg/kg intravenous treatment plus standard systemic lupus erythematosus therapy. Analyses of vaccine titers were performed on the as-treated population (received ≥1 dose of belimumab). The primary endpoint was the proportion of patients with positive antibody responses (≥2-fold increase from pre-vaccination levels, or post-vaccination level ≥ 0.6 µg/mL if pre-vaccination levels were unquantifiable) to ≥1 of 23 pneumococcal vaccine serotypes, four weeks post vaccination. Other endpoints included the proportion of patients with positive antibody responses to ≥2 to ≥10, and ≥11–23 (post hoc analysis) of serotypes. Safety was assessed by monitoring adverse events. RESULTS: Seventy-nine patients received pneumococcal vaccination (pre-belimumab cohort, n = 34; belimumab-concurrent cohort, n = 45). The majority (87.3% [69/79]) completed the study; 10 (12.7%) withdrew (patient request, n = 3; adverse event, n = 3; lost to follow-up, n = 2; other, n = 2). At Week 4 post-vaccination, 97.0% (32/33) and 97.6% (40/41) of patients (pre-belimumab and concurrent belimumab cohorts, respectively) had a positive response to ≥1 of 23 pneumococcal serotypes. Over 85% of patients in both cohorts responded to ≥10 of serotypes, approximately 80% responded to ≥12 serotypes, and approximately two-thirds responded to ≥16 serotypes. Little difference was observed between cohorts across a broad response, up to 23 serotypes. Eight (23.5%) patients experienced an adverse event considered by the investigator to be treatment-related in the pre-belimumab cohort and four (8.9%) in the belimumab-concurrent cohort; seven patients experienced non-fatal serious adverse events (pre-belimumab cohort, 11.8% [n = 4]; concurrent-belimumab cohort, 6.7% [n = 3]), and no deaths were reported. CONCLUSION: The proportion of patients generating a response to ≥1 pneumococcal serotype did not differ between the pre-belimumab and belimumab-concurrent cohorts; the proportions were also comparable across a broader response (from ≥2 serotypes to 23 serotypes). SAGE Publications 2017-05-03 2017-12 /pmc/articles/PMC5673008/ /pubmed/28467293 http://dx.doi.org/10.1177/0961203317703495 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Papers Chatham, W Chadha, A Fettiplace, J Kleoudis, C Bass, D Roth, D Gordon, D A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus |
title | A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus |
title_full | A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus |
title_fullStr | A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus |
title_full_unstemmed | A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus |
title_short | A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus |
title_sort | randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus |
topic | Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673008/ https://www.ncbi.nlm.nih.gov/pubmed/28467293 http://dx.doi.org/10.1177/0961203317703495 |
work_keys_str_mv | AT chathamw arandomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT chadhaa arandomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT fettiplacej arandomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT kleoudisc arandomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT bassd arandomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT rothd arandomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT gordond arandomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT chathamw randomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT chadhaa randomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT fettiplacej randomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT kleoudisc randomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT bassd randomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT rothd randomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus AT gordond randomizedopenlabelstudytoinvestigatetheeffectofbelimumabonpneumococcalvaccinationinpatientswithactiveautoantibodypositivesystemiclupuserythematosus |